This study is looking at new ways to image head and neck squamous cell carcinoma (a type of cancer). It compares a special imaging scan using [89Zr]Panitumumab-PET/MRI with the standard imaging scan, (18F-FDG)-PET/MRI. The goal is to see if the new scan can more accurately show the size and location of tumors before surgery. You could join if you have newly diagnosed head and neck squamous cell carcinoma, are scheduled for surgery, and your cancer has not spread to lymph nodes. This study is for imaging only and will not change your treatment plan. Researchers will measure the quality of the images taken 5-9 days before your surgery. The study is currently unclear on its recruitment status and plans to enroll 14 participants.

Study design

This is a single-center, non-randomized pilot study. It is open-label, meaning both you and the study team will know which imaging agent you receive. It plans to include 14 participants.

What's involved

You will have [89Zr]Panitumumab-PET/MRI imaging. You will also have a phone call to discuss the study and complete an MRI screening form before your first visit.

Compensation

Not stated in the trial record.

Follow-up

Image quality will be measured 5-9 days prior to surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.